A ~96-person device company built one contrarian idea: an implant that provides stent-strength first, then lets go - so the coronary artery can move again.
The logo of a company whose whole pitch is restraint - a piece of metal engineered to know when to stop holding on. Milpitas, California.
Here is a fact about coronary stents that is either obvious or slightly unsettling, depending on how much you think about it: once one goes into your artery, it stays there. Forever. A tiny permanent scaffold, holding a vessel open, and also - this is the part cardiologists have argued about for thirty years - holding it rigid. Arteries are supposed to pulse. A caged one doesn't.
Elixir Medical Corporation, a privately held company in Milpitas, California, has spent roughly two decades on a single stubborn question: what if the implant let go? Its flagship product, the DynamX Coronary Bioadaptor, is a metal implant with a bioresorbable polymer coating. For the first six months it behaves like a good drug-eluting stent - radial strength, sirolimus doing its anti-restenosis work. Then the polymer dissolves, the implant "uncages," and the artery is free to expand and contract with its own natural motion. The company reports restored vessel pulsatility and compliance, adaptive increases in blood flow, and - the phrase that makes interventional cardiologists lean in - plaque stabilization and regression.
The bioadaptor's trick is almost paradoxical: it's a permanent piece of metal engineered to stop behaving like one.
You can be skeptical of this. Plenty of people were skeptical of Elixir's earlier idea, too - the DESolve, a fully bioresorbable scaffold that was supposed to vanish entirely and let the artery heal on its own. The broader bioresorbable-scaffold field ran into real trouble in the mid-2010s, and Elixir did not conquer the market with it. But the interesting companies are often the ones that treat a stumble as feedstock rather than an ending. The lesson Elixir seems to have extracted - that "disappear completely" was too much, but "hold on, then let go" might be just right - is what became the bioadaptor.
The reason anyone outside a cath lab is talking about this is the data. Not one trial but two, which in medical devices is unusual - most companies ship on a single positive result and move on. Elixir ran it back.
Target lesion failure bundles cardiac death, target-vessel heart attack, and repeat revascularization into one endpoint. It is the number cardiologists trust because it is hard to dress up. Elixir's claim is that in a prespecified landmark analysis, the DynamX curve separated from the stent curve and stayed separated.
Indexed to the comparator stent at 100. Directional illustration of published relative reduction - see the INFINITY-SWEDEHEART presentations for full hazard ratios and confidence intervals.
Elixir's product line reads like a twenty-year argument with the coronary stent - each device a slightly different answer to "how much implant does an artery actually need?"
Sirolimus-eluting metal implant with a resorbable polymer coating. Stent-strength up front, then it uncages the artery to restore pulsatility, compliance and adaptive blood flow - associated with plaque stabilization and regression.
A thin-strut durable drug-eluting stent in Elixir's DESyne family - the conventional-category entry that anchors the company's coronary lineup.
An intravascular lithotripsy system that fractures coronary calcium to prepare hardened, calcified lesions before a stent or bioadaptor goes in.
The earlier fully bioresorbable novolimus-eluting scaffold. DESolve 100, with 100-micron struts, earned a CE Mark as one of the thinnest bioresorbable scaffolds of its era.
"We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come."
The most useful critics tend to come from inside the thing they're rethinking. Motasim Sirhan started his career at Guidant Corporation, where he worked on catheter systems and led several first-of-category products - including the RX Perfusion PTCA catheter, PET balloon technology, and the market-leading Multi-Link stent. Then he left to build.
He founded and exited Avantec Vascular, co-founded Maya Medical, and served on the board of Apama Medical - before starting Elixir Medical in 2005 with backing from the Invus Group. He holds an M.S. in Biomedical Engineering, an M.S. in Management, and dual B.S. degrees in Biomedical and Electrical Engineering, and is an inventor on dozens of issued and pending patents. He was once named to the Silicon Valley Business Journal's "30 under 30."
Learn an industry's craft cold, then decide what's worth keeping.
Motasim Sirhan starts the company in Milpitas with backing from the Invus Group.
Completes enrollment of a 15-patient first-in-man study of its fully bioresorbable drug-eluting scaffold.
The novolimus-eluting bioresorbable coronary scaffold clears European regulatory approval.
CE Mark for the 100-micron-strut DESolve 100; first commercial implant performed in Germany.
INFINITY-SWEDEHEART hits its endpoint at ESC Congress; DynamX granted FDA Breakthrough Device Designation.
EuroPCR and TCT late-breakers show sustained lower event rates vs. drug-eluting stent through three years.
New DynamX data again show significantly lower event rates than a drug-eluting stent.
For interventional cardiologists, the bioadaptor is a third option that sits between a permanent stent and a fully resorbable scaffold - a way to treat a coronary lesion while leaving the vessel able to move afterward. It slots into the same percutaneous coronary intervention workflow, alongside Elixir's LithiX calcium-fracture system for the hard cases.
For patients with coronary artery disease, the promise is longer-term: fewer downstream events, an artery that behaves more like an artery. As of the latest public information DynamX holds European CE Mark and an FDA Breakthrough designation, but is not yet approved for U.S. sale - so availability depends on where you are.
For the medtech field, Elixir is a case study in evidence-first competition. A company of roughly 96 people, outside the traditional device hubs of Boston and Minneapolis, going head-to-head with Abbott, Boston Scientific and Medtronic on the only currency that travels: randomized data.
Implantable devices for coronary and peripheral artery disease: the DynamX bioadaptor, DESyne drug-eluting stents, the LithiX intravascular lithotripsy system, and the earlier DESolve bioresorbable scaffold.
It gives stent-like strength at first, but its resorbable polymer dissolves over about six months, uncaging the artery so the vessel can pulse and move naturally instead of staying rigidly caged.
It holds European CE Mark and received FDA Breakthrough Device Designation in 2024, but as of the latest public information it is not yet approved for sale in the U.S.
Motasim Sirhan, in 2005. He previously worked at Guidant and founded Avantec Vascular, and remains Founder and CEO.
INFINITY-SWEDEHEART reported roughly a 48% reduction in target lesion failure versus a contemporary drug-eluting stent from six months through two years, with benefits sustained through three years.
SOURCES: GlobeNewswire & PCRonline (INFINITY-SWEDEHEART / EuroPCR / TCT releases), BusinessWire (FDA Breakthrough Device), Cardiac Interventions Today, DAIC, MassDevice, Cardiovascular Business, Crunchbase, PitchBook, and elixirmedical.com. Clinical figures are as reported by the company and conference presentations; treat trial numbers as approximate and see primary presentations for full statistics.